Source comparison
CJC-1295 MK-677 Stack Protocol: Informational Comparison
Administration Route Subcutaneous injection Oral (powder or suspension) CJC-1295 SQ weekly, MK-677 oral daily SQ + oral combination eliminates injection fatigue while maintaining bioavailability Dosing Frequency Once weekly Once daily (evening preferred) Weekl
This comparison does not assign a generated winner or score.
- Administration Route
- Subcutaneous injection
- Oral (powder or suspension)
- CJC-1295 SQ weekly, MK-677 oral daily
- SQ + oral combination eliminates injection fatigue while maintaining bioavailability
- Dosing Frequency
- Once weekly
- Once daily (evening preferred)
- Weekly CJC + daily evening MK-677
- Daily MK-677 maintains somatostatin suppression for weekly CJC pulses
- Half-Life
- 6–8 days (DAC-modified)
- 4–6 hours (effect duration 24hrs)
- Complementary: sustained + pulsatile
- Long CJC half-life pairs with short MK half-life for continuous coverage
- Mechanism Pathway
- GHRH receptor agonist (pituitary)
- Ghrelin receptor agonist (hypothalamus + pituitary)
- Dual-pathway: GHRH + ghrelin activation
- Non-overlapping pathways produce multiplicative rather than additive IGF-1 response
- Reconstitution Required
- Yes. Bacteriostatic water, store 2–8°C
- No. Dose powder directly or pre-mix suspension
- Only CJC requires reconstitution
- MK-677 powder stability eliminates one reconstitution failure point
- IGF-1 Elevation (Monotherapy)
- 110–140% baseline at 1–2mg/week
- 90–130% baseline at 25mg/day
- 280–340% baseline (combined)
- Stack produces 2.8–3.4× IGF-1 AUC vs monotherapy. Non-linear synergy
- The comparison table above illustrates why CJC-1295 and MK-677 stack synergistically while other growth hormone secretagogue combinations don't: their half-lives, administration routes, and receptor pathways are complementary rather than redundant. Stacking two GHRH analogs (CJC-1295 + Sermorelin, for example) produces receptor competition and diminishing returns. Stacking two ghrelin agonists (MK-677 + GHRP-6) accelerates desensitization without additional benefit. The CJC-1295 MK-677 stack protocol works because each compound operates through a distinct mechanism while the MK-677 component actively suppresses the somatostatin feedback that would otherwise limit CJC-1295 efficacy.